3-Year Safety and Efficacy of PCRX-201 in Knee Osteoarthritis
Pacira BioSciences announced Phase 1 data for its gene therapy candidate PCRX-201 (enekinragene inzadenovec) at the 2025 European Alliance...
Actuate Therapeutics Announces Topline Results From Phase 2 Elraglusib Trial
Actuate Therapeutics announced positive topline results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for first-line...
Galimedix Phase 1 Dose Study of Oral Gal-101 Complete
Galimedix Therapeutics has completed the single ascending dose (SAD) portion of its Phase 1 study for oral GAL-101, a...
Barzolvolimab Shows Promise in Eosinophilic Esophagitis Phase 2 Study
Celldex presented histology data from its Phase 2 trial of barzolvolimab for eosinophilic esophagitis (EoE) at the 2025 Digestive...
Capricor Gets FDA Nod for DMD Cardiomyopathy Drug Trial
Capricor Therapeutics announced the completion of a mid-cycle review meeting with the FDA for its Biologics License Application (BLA)...
WTX-921 Shows Promising Preclinical Data for IBD Treatment
Werewolf Therapeutics presented data at IMMUNOLOGY2025 demonstrating the efficacy of WTX-921, a conditionally activated IL-10 drug, in a mouse...
OPGX-LCA5 Gene Therapy Restores Meaningful Vision in Phase 1/2 Trial
Opus Genetics announced one-year results from a Phase 1/2 study of its lead gene therapy candidate, OPGx-LCA5, for patients...
UBX1325 DME Phase 2b Study: 36-Week Results & Corporate Updates
UNITY Biotechnology announced 36-week results from its Phase 2b ASPIRE trial of UBX1325 for diabetic macular edema (DME). The...
Chemomab Announces Positive Phase 2 Nebakitug Clinical Data in PSC at DDW 2025
Chemomab Therapeutics announced positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at Digestive...
FDA Grants Fast Track to Alterity’s ATH434 for Multiple System Atrophy
Alterity Therapeutics has received Fast Track designation from the U.S. FDA for ATH434, a treatment for Multiple System Atrophy...